CRCS12; FILS; POLE1
The POLE gene is associated with an increased risk for autosomal dominant colonic adenomatous polyps and colon cancer (PMID: 23263490, 26133394, 23585368, 24501277, 24788313). Additionally, the POLE gene is associated with autosomal recessive facial dysmorphism, immunodeficiency, livedo, and short stature (FILS) syndrome (PMID: 23230001, 25948378).
Order this gene as a single gene test.
Invitae tests that include this gene:
The POLE gene encodes the catalytic subunit of DNA polymerase epsilon, an enzyme that plays a critical role in DNA replication and repair.
MedGen UID: 430218
Pathogenic variants in the POLD1 and POLE genes are associated with a recently defined, highly penetrant autosomal dominant colorectal cancer predisposition syndrome whose proposed name is polymerase proofreading-associated polyposis syndrome (PPAP) (PMID: 24509466, 26133394, 25529843, 26822575). Individuals with a single pathogenic POLE variant typically have a more attenuated colorectal phenotype, regularly presenting before the age of 60 with colorectal cancer (often microsatellite stable) or fewer than 100 adenomas (PMID: 25529843, 23263490, 24501277, 23585368). The clinical spectrum ranges from large polyps (>2 cm in diameter) to multiple adenomas resembling attenuated familial adenomatous polyposis (AFAP) to MUTYH-associated polyposis syndrome (MAP) (PMID: 25529843). Many cases may also have a family history of clustering of early-onset colorectal cancer similar to what is typically seen in Lynch syndrome (also called hereditary non-polyposis colorectal cancer, or HNPCC), although some have no such history (PMID: 25529843).
PPAP is associated with an increased risk of gastroduodenal (mostly duodenal) adenomas and malignancy; however, this risk appears limited to those with a POLE pathogenic variant (PMID: 26133394, 25529843, 24788313). Other reported extra-gastrointestinal findings observed in those with a pathogenic POLE variant include pilomatricomas, retroperitoneal fibrosis, lipoma, and fibromas (PMID: 25529843).
There is preliminary evidence suggesting women with PPAP may have an increased risk of endometrial cancer; however, this risk appears to be limited to those with a POLD1 pathogenic variant (PMID: 26133394, 25529843, 23263490, 26822575). The risk for other cancers may also be elevated; however, this evidence is limited and emerging (PMID: 23263490, 26133394, 25529843, 26822575). An individual with a POLE pathogenic variant will not necessarily develop cancer in their lifetime, but the risk of cancer is increased over the general population risk.
The POLE gene plays a critical role in DNA replication and repair (Gene. Gene ID: 5426. http://www.ncbi.nlm.nih.gov/gene/5426 Accessed March 2018). POLE and POLD1 encode the catalytic and proofreading subunits of the polymerase enzyme complexes e (Pol d) and d (Pol e), respectively. These subunits are involved in synthesis regulation and cofactor binding (PMID: 25529843). If there is a pathogenic variant in this gene that prevents it from functioning normally, the risk of developing certain types of cancers is increased.
Hereditary predisposition to cancer due to pathogenic variants in the POLE gene has autosomal dominant inheritance. This means that an individual with a pathogenic variant has a 50% chance of passing the condition on to their offspring. Once a pathogenic mutation is detected in an individual, it is possible to identify at-risk relatives who can pursue testing for this specific familial variant. Most cases are inherited from a parent, but some cases can occur spontaneously (i.e., an individual with a pathogenic variant has parents who do not have it) (PMID: 25529843). An individual with a variant in POLE has a 50% risk of passing that variant on to offspring.
The POLE gene has preliminary evidence supporting a correlation with autosomal recessive facial dysmorphism, immunodeficiency, livedo, and short stature (FILS) syndrome (PMID: 23230001, 25948378). FILS is an autosomal recessive condition that is characterized by mild facial dysmorphism, immunodeficiency resulting in recurrent infections, livedo on the skin that is present at birth, and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001, 25948378)). For there to be a risk of FILS in offspring, a patient and their partner would each have to have a single pathogenic variant in POLE; in such a case, the risk of having an affected child is 25%.
Medical management and surveillance protocols for individuals with a pathogenic variant in POLE have been developed by the National Comprehensive Cancer Network® (NCCN) (NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Colorectal. Version 3.2017):
Because endometrial cancer has so far only been reported in individuals with POLD1 pathogenic variants, no specific surveillance regarding endometrial cancer screening is currently suggested for those with a pathogenic variant in POLE (PMID: 26133394, 25529843)).
An individual’s cancer risk and medical management are not determined by genetic test results alone. Overall cancer risk assessment incorporates additional factors, including personal medical history, family history, and any available genetic information that may result in a personalized plan for cancer prevention and surveillance.
Knowing if a pathogenic variant is present in POLE is advantageous. At-risk relatives can be identified, enabling pursuit of a diagnostic evaluation. Further, the available information regarding hereditary cancer susceptibility genes is constantly evolving and more clinically relevant data regarding POLE are likely to become available in the near future. Awareness of this cancer predisposition encourages patients and their providers to inform at-risk family members, to diligently follow published screening protocols, and to be vigilant in maintaining close and regular contact with their local genetics clinic in anticipation of new information.
Referenced with permission from the NCCN Genetic/Familial High-Risk Assessment: Colorectal. Version 3.2017. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed February 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Review date: March 2018
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below. In addition, the analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|